| 20.38 -0.85 (-4%) | 11-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.45 |
1-year : | 32.07 |
| Resists | First : | 23.51 |
Second : | 27.45 |
| Pivot price | 21.03  |
|||
| Supports | First : | 18.11 |
Second : | 14.77 |
| MAs | MA(5) : | 20.98 |
MA(20) : | 20.58 |
| MA(100) : | 14.09 |
MA(250) : | 7.8 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 49.5 |
D(3) : | 55.5 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 30.35 | Low : | 2.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NBTX ] has closed above bottom band by 28.8%. Bollinger Bands are 55.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.55 - 20.69 | 20.69 - 20.8 |
| Low: | 18.89 - 19.02 | 19.02 - 19.12 |
| Close: | 20.18 - 20.4 | 20.4 - 20.58 |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Mon, 24 Nov 2025
Nanobiotix (NASDAQ: NBTX) details €20.4M cash and 2026 clinical data outlook - Stock Titan
Mon, 24 Nov 2025
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook - GlobeNewswire
Fri, 14 Nov 2025
Nanobiotix (NASDAQ: NBTX) posts 50.25M exercisable voting rights, 48.24M shares - Stock Titan
Mon, 03 Nov 2025
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th - GlobeNewswire
Fri, 31 Oct 2025
Nanobiotix S.A. (NBTX) Stock: 2.5% Jump as $71M Boost Strengthens Pipeline and Financial Foundation - parameter.io
Fri, 31 Oct 2025
Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Ro - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 11.7 (%) |
| Shares Short | 42 (K) |
| Shares Short P.Month | 74 (K) |
| EPS | -1.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.43 |
| Profit Margin | 0 % |
| Operating Margin | 3 % |
| Return on Assets (ttm) | -41.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 186.8 % |
| Gross Profit (p.s.) | 0.21 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -0.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -16.05 |
| PEG Ratio | 0 |
| Price to Book value | -14.26 |
| Price to Sales | 96.72 |
| Price to Cash Flow | -31.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|